Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Procter & Gamble Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Procter & Gamble Co trades at $147.48 (market cap $342.40B). The key difference: Procter & Gamble Co is far larger — about 8.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Procter & Gamble Co pays a 2.9% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PG | |
|---|---|---|
Market Cap | $39.89B | $342.40B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $167.18 |
52-Week Low | $278.09 | $138.10 |
Enterprise Value | $38.15B | $367.88B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Procter & Gamble (PG) trades at $147.04, up 0.13% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock is supported by strong fundamentals, including consistent earnings beats, a 19.16% net income margin, and a dividend track record with a recent $1.09 payout. Revenue growth remains modest, with 2025 revenue at $84.28B, while valuation ratios like a P/E of 21.5 reflect a premium to peers. Recent news highlights PG's supply chain enhancements and a new WNBA partnership, though some analysts question near-term upside due to soft demand.
The outlook for PG is cautiously optimistic, with a consensus price target of $159.75 implying potential upside. Strengths include stable cash flow and brand resilience, but risks involve premium valuation pressures and macroeconomic headwinds. Investors may find value in its dividend consistency and operational efficiency, though volatility from market sentiment warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
